About CEL-SCI (NYSEAMERICAN:CVM)
CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for treatment of certain head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus and human papillomavirus co-infected patients and Ligand Epitope Antigen Presentation System (L.E.A.P.S.) technology, with over two investigational therapies, LEAPS-H1N1-DC, a product candidate under development for treatment of pandemic influenza in hospitalized patients, and CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis.
Industry, Sector and Symbol:
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Sector: N/A
- Symbol: NYSEAMERICAN:CVM
- CUSIP: N/A
- Web: www.cel-sci.com
- Trailing EPS: ($1.30)
- Net Margins: -25,564.75%
- Return on Assets: -207.79%
- Outstanding Shares: 11,830,000
Frequently Asked Questions for CEL-SCI (NYSEAMERICAN:CVM)
What is CEL-SCI's stock symbol?
CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."
How were CEL-SCI's earnings last quarter?
CEL-SCI Co. (NYSEAMERICAN:CVM) posted its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.05) EPS for the quarter. The company had revenue of $0.02 million for the quarter. View CEL-SCI's Earnings History.
When will CEL-SCI make its next earnings announcement?
Are investors shorting CEL-SCI?
CEL-SCI saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 583,301 shares, a drop of 12.8% from the October 13th total of 668,765 shares. Based on an average trading volume of 162,314 shares, the days-to-cover ratio is presently 3.6 days. Currently, 5.3% of the shares of the company are sold short.
Who are some of CEL-SCI's key competitors?
Some companies that are related to CEL-SCI include Egalet Corporation (EGLT), Microbot Medical (MBOT), Xenon Pharmaceuticals (XENE), Imprimis Pharmaceuticals (IMMY), ContraVir Pharmaceuticals (CTRV), Catabasis Pharmaceuticals (CATB), Vical Incorporated (VICL), Auris Medical Holding AG (EARS), Avacta Group Plc (AVCT), Proteon Therapeutics (PRTO), Celsion Corporation (CLSN), Anthera Pharmaceuticals (ANTH), ANGLE plc (AGL), Orexigen Therapeutics (OREX), Zosano Pharma Corporation (ZSAN), Redx Pharma PLC (REDX), Pain Therapeutics (PTIE) and Midatech Pharma PLC (MTPH).
Who are CEL-SCI's key executives?
CEL-SCI's management team includes the folowing people:
- Geert R. Kersten Esq., Chief Executive Officer, Treasurer, Director (Age 56)
- Patricia B Prichep, Senior Vice President - Operations, Corporate Secretary (Age 63)
- John Cipriano, Senior Vice President - Regulatory Affairs (Age 72)
- Daniel H Zimmerman Ph.D., Senior Vice President - Research, Cellular Immunology (Age 73)
- Eyal Talor Ph.D., Chief Scientific Officer (Age 58)
- Alexander G. Esterhazy, Independent Director (Age 73)
- Peter R. Young Ph.D., Independent Director (Age 70)
How do I buy CEL-SCI stock?
Shares of CEL-SCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CEL-SCI's stock price today?
One share of CEL-SCI stock can currently be purchased for approximately $1.90.
How big of a company is CEL-SCI?
CEL-SCI has a market capitalization of $23.15 million.
How can I contact CEL-SCI?
CEL-SCI's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The company can be reached via phone at +1-703-5069460.
MarketBeat Community Rating for CEL-SCI (NYSEAMERICAN CVM)MarketBeat's community ratings are surveys of what our community members think about CEL-SCI and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for CEL-SCI (NYSEAMERICAN:CVM) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 0 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Hold (Score: 2.00)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for CEL-SCI (NYSEAMERICAN:CVM)
Analysts' Ratings History for CEL-SCI (NYSEAMERICAN:CVM)
(Data available from 11/20/2015 forward)
|10/16/2017||Dawson James||Reiterated Rating||Neutral|
Earnings History and Estimates Chart for CEL-SCI (NYSEAMERICAN:CVM)
Earnings History by Quarter for CEL-SCI (NYSEAMERICAN CVM)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/10/2017||Q2 2017||($0.05)||$0.02 million||View||N/A|
|5/8/2015||Q2 2015||($0.12)||($0.17)||$0.10 million||$0.20 million||View||N/A|
|2/6/2015||Q1 2015||($0.09)||($0.11)||$0.07 million||$0.14 million||View||N/A|
|5/13/2014||Q114||($0.11)||($0.24)||$0.02 million||$0.07 million||View||N/A|
Earnings Estimates for CEL-SCI (NYSEAMERICAN:CVM)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for CEL-SCI (NYSEAMERICAN:CVM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for CEL-SCI (NYSEAMERICAN CVM)
Insider Trades by Quarter for CEL-SCI (NYSEAMERICAN CVM)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/17/2017||Vicente Benjamin Asuncion||Director||Sell||160,000||$0.39||$62,400.00|
|8/25/2017||Eyal Talor||Insider||Sell||769||$1.91||$1,468.79|| |
|8/16/2017||Eyal Talor||Insider||Sell||14,019||$2.61||$36,589.59|| |
|10/13/2014||Geert R Kersten||CEO||Buy||14,999||$0.77||$11,549.23|| |
|12/30/2013||Geert R Kersten||CEO||Buy||300,000||$0.60||$180,000.00|| |
|10/9/2013||Geert R Kersten||Insider||Buy||8,400||$0.79||$6,636.00|| |
|6/19/2013||Peter R Young||Director||Buy||25,000||$0.24||$6,000.00|| |
|6/14/2013||Geert R Kersten||Insider||Buy||145,120||$0.24||$34,828.80|| |
|5/20/2013||Geert R Kersten||CEO||Buy||40,000||$0.25||$10,000.00|| |
|5/2/2013||Geert R Kersten||CEO||Buy||118,700||$0.27||$32,049.00|| |
|3/27/2013||Peter R Young||Director||Buy||25,000||$0.23||$5,750.00|| |
|3/26/2013||Geert R Kersten||CEO||Buy||348,125||$0.21||$73,106.25|| |
Latest Headlines for CEL-SCI (NYSEAMERICAN CVM)
CEL-SCI (NYSEAMERICAN CVM) Chart for Monday, November, 20, 2017